Read by QxMD icon Read


Gergely Horváth, Teodóra Keleti, Mihály Makara, Gabor S Ungvari, Gábor Gazdag
PURPOSE: To assess the quality of life (QoL) of patients with hepatitis C infection (HCI) and its correlations with demographic and clinical variables. DESIGN AND METHODS: QoL and depressive symptoms were evaluated with the validated rating instruments of the 36-item short form (SF-36) generic health survey and the second version of the self-rated Beck depression inventory (BDI-II) in a cross-sectional design and correlated with basic demographic and clinical variables, including the Fibroscan score, which indicates the severity of liver impairment...
March 12, 2018: Perspectives in Psychiatric Care
Norio Akuta, Joji Toyota, Yoshiyasu Karino, Fusao Ikeda, Akio Ido, Katsuaki Tanaka, Koichi Takaguchi, Atsushi Naganuma, Eiichi Tomita, Kazuaki Chayama, Shigetoshi Fujiyama, Yukiko Inada, Hitoshi Yoshiji, Hideaki Watanabe, Hiroki Ishikawa, Fiona McPhee, Stephanie Noviello, Hiromitsu Kumada
BACKGROUND: In the UNITY-3 study, 96% sustained virologic response (SVR12) rate was observed in Japanese patients with hepatitis C virus (HCV) genotype (GT)-1 infection treated for 12 weeks with fixed-dose daclatasvir, asunaprevir, and beclabuvir (DCV-TRIO). As HCV clearance may improve liver outcomes, we assessed hepatic fibrosis and alpha-fetoprotein (AFP), a hepatocellular carcinoma risk marker, pre- and post-treatment in UNITY-3. METHODS: Treatment-naive or interferon-experienced UNITY-3 patients with HCV GT-1 who received twice-daily DCV-TRIO were assessed for fibrosis [FibroTest; FibroScan; fibrosis-4 index (FIB-4), aspartate-aminotransferase-to-platelet-ratio index] and AFP at baseline and Weeks 4 (FIB-4 only), 12 or 24 post-treatment...
March 2, 2018: Journal of Gastroenterology
Jayanta Paul, Raj Vigna Venugopal, Lorance Peter, Shihaz Hussain, Kula Naresh Kumar Shetty, Mohit P Shetti
Background and aims: Non-alcoholic fatty liver disease (NAFLD) is remarkably increasing in developing countries like India, in parallel with the increasing incidence of obesity. Lifestyle modification is a recommended treatment for NAFLD. In most of the previous studies, improvement after lifestyle modification was assessed by liver fibrosis through liver biopsy, but we cannot do a serial liver biopsy in every NAFLD patient. Liver fibrosis can also be assessed by fibroscan non-invasively in NAFLD...
February 2018: Gastroenterology Report
Hend Ibrahim Shousha, Rasha Ahmed Abdelaziz, Sherief Musa Azab, Marwa Khairy, Shahira Ahmed Afifi, Mai Ismael Mehrez, Mohamed Ali Eshra, Ayman Yosry Abdelrahim
BACKGROUND: Direct Acting Agents (DAAs) have high cure rate but still lack the knowledge of their effect on hepatic steatosis in chronic hepatitis C (CHC). Controlled Attenuation Parameter (CAP), evaluated with transient elastography, could help in assessment of steatosis grades. We aim to evaluate the effect of DAAs on BMI and steatosis in CHC using CAP. PATIENTS AND METHODS: This cohort study included 155 CHC Egyptian patients divided into three groups according to the DAAs regimens...
February 22, 2018: Journal of Medical Virology
Barbara Castelnuovo, Frank Mubiru, Agnes N Kiragga, Rachel Musomba, Olive Mbabazi, Paul Gonza, Andrew Kambugu, Rosalind Parks Ratanshi
PURPOSE: Little information is available on patients on antiretroviral treatment (ART) after a long-term period from sub-Saharan Africa, with the longest follow-up and related outcomes being after 10 years on ART. At the Infectious Diseases Institute (IDI) (Kampala, Uganda), we set up a cohort of patients already on ART for 10 years at the time of enrolment, who will be followed up for additional 10 years. PARTICIPANTS: A prospective observational cohort of 1000 adult patients previously on ART for 10 years was enrolled between May 2014 and September 2015...
February 21, 2018: BMJ Open
Mira Choi, Jörg Hofmann, Anja Köhler, Bo Wang, Claus-Thomas Bock, Eckart Schott, Petra Reinke, Peter Nickel
Background: Elevated liver enzymes are frequently observed in renal transplant recipients and warrant further exploration. In immunosuppressed patients, hepatitis E virus (HEV) infection may cause chronic hepatitis, cirrhosis, and extrahepatic manifestations such as renal injury. Methods: We performed a retrospective cross-sectional study investigating the prevalence, clinical correlates, and outcome of chronic HEV infection in a cohort of renal transplant recipients with elevated liver enzymes...
February 2018: Transplantation Direct
Ghada El Sagheer, Elwy Soliman, Asmaa Ahmad, Lamiaa Hamdy
Chronic hepatitis C virus (HCV) infection is associated with altered metabolism, including dyslipidemia and insulin resistance. These contribute to disease progression and influences the response to therapy. To investigate the relationships of new direct-acting antiviral drugs, simeprevir/sofosbuvir, with lipid profile and insulin resistance (IR). Eighty chronic hepatitis C genotype 4 patients were included; they were divided into four groups according to the severity of fibrosis as detected by fibroscan. Forty healthy persons volunteered as a control group...
December 2018: Libyan Journal of Medicine
Rasha Eletreby, Mohamed Said, Zeinab Abdellatif, Yasmin Saad, Magdy ElSerafy, Hosam Dabes, Kadry ElSaeed, Yehia El-Shazly, Wahid Doss
BACKGROUND: HCV is associated with several extra hepatic diseases including thyroid dysfunction. This study aims at evaluating prevalence of thyroid dysfunction and its possible predictors in a large cohort of HCV GT4-infected patients, and the role of thyroid dysfunction as a predictor of response in the setting of direct acting antivirals (DAAs). METHODS: Patients registered on the web-based registry system to receive therapy for chronic HCV in Beheira governorate viral hepatitis specialized treatment center affiliated to the National committee for control of viral hepatitis (NCCVH), Ministry of health, Egypt in the period from January 2015 to October 2016...
February 14, 2018: Hepatology International
Natasha Kamal, Pallavi Surana, Christopher Koh
PURPOSE OF REVIEW: The aim of this study was to provide an overview of the current understanding of the pathophysiology, diagnosis and management of cystic fibrosis-liver disease (CFLD). RECENT FINDINGS: CFLD has a variety of manifestations. Previously, it was thought that patients progressed from mild cholestatic disease to cirrhosis to decompensated cirrhosis with portal hypertension. Newer evidence suggests that some patients may develop cirrhosis while others develop noncirrhotic portal hypertension...
February 12, 2018: Current Opinion in Gastroenterology
Shufei Zang, Jin Chen, Yu Song, Lang Bai, Jinjun Chen, Xiaoling Chi, Fangping He, Huiping Sheng, Jing Wang, Shilong Xie, Wen Xie, Yongfeng Yang, Jing Zhang, Minghua Zheng, Zhengsheng Zou, Bingyuan Wang, Junping Shi
INTRODUCTION: Vitamin E is one of the most promising agents for nonalcoholic steatohepatitis (NASH) treatment, and its drug responsiveness may be closely associated with haptoglobin (Hp) genotype. However, its efficacy and safety remain unknown in China. This clinical trial of vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis (VENS) is conducted to evaluate (a) the efficacy and safety of treatment with vitamin E softgel (300 mg/day) determined from standardized histologic scoring of liver biopsies, (b) whether treatment with vitamin E improves biochemical parameters, cytokines, anthropometric parameters, controlled attenuation parameter (CAP), and transient elastography (TE) values determined by Fibroscan and health-related quality of life (SF-36), (c) whether the efficacy of vitamin E treatment is associated with the Hp genotype in nondiabetic adults with NASH...
February 6, 2018: Advances in Therapy
Magnus Hedenstierna, Ali Nangarhari, Amin El-Sabini, Ola Weiland, Soo Aleman
We aimed to assess fibrosis with liver stiffness measurement long-term after sustained virologic response of chronic hepatitis C, and to identify risk factors associated with persisting fibrosis. In this cross-sectional study, patients with chronic hepatitis C and pre-treatment advanced fibrosis or cirrhosis treated successfully at Karolinska University Hospital with an interferon-containing regimen, underwent liver stiffness measurement with FibroScan. The impact of potential risk factors for persisting fibrosis was estimated...
February 6, 2018: Journal of Viral Hepatitis
Mona A Abu El Makarem, Ghada M El-Sagheer, Moustafa A Abu El-Ella
<br>To investigate the possible role of STAT5 in the pathogenesis of liver fibrosis in Egyptian patients with chronic hepatitis C (CHC) virus infection and its relation to hepatic stellate cells (HSCs). <br> Materials (Subjects) and Methods<br>Sixty-five patients (46/19 male/ female ratio) were divided into 4 groups based on the severity of fibrosis as detected by fibroscan, (15 F1, 21 F2, 13 F3, and 16 F4). Twenty, age- and gender-matched, healthy persons volunteered as a control. The serum levels of STAT5, TGF-β1, α-SMA, fasting blood sugar (FBS), fasting insulin and homeostasis model assessments of insulin resistance (HOMA-IR) were determined and compared for all groups...
January 31, 2018: Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre
Jing Li, Ri-Cheng Mao, Xiao-Ling Li, Jin-Wei Zheng, Xun Qi, Quan Yuan, Jun Zhang, Ji-Ming Zhang, Ning-Shao Xia
BACKGROUNDS: The evaluation of liver fibrosis stages is essential for the clinical management of chronic hepatitis B (CHB). AIMS: To develop and validate a novel noninvasive index for moderate to severe fibrosis (≥S2) in CHB patients. METHODS: A total of 401 CHB patients who underwent liver biopsy were divided into the training (n = 300) and validation (n = 101) cohort. Histological severity was scored using a modified Scheuer system...
January 5, 2018: Digestive and Liver Disease
Jacqueline Bachofner, Piero V Valli, Irina Bergamin, Arne Kröger, Patrizia Künzler, Adriana Baserga, Dominique L Braun, Burkhardt Seifert, Anja Moncsek, Jan Fehr, David Semela, Lorenzo Magenta, Beat Müllhaupt, Benedetta Terziroli Beretta-Piccoli, Joachim Mertens, The Swiss Hepatitis C Cohort Study
BACKGROUND: The introduction of direct acting antivirals (DAAs) for the therapy of chronic hepatitis C (CHC) has revolutionised treatment and marks a paradigm shift in the approach to this disease, rendering interferon-based therapies obsolete. AIMS OF THE STUDY: We retrospectively and prospectively evaluated treatment results after the introduction of DAA in Switzerland in a cohort of patients with CHC. METHODS: We examined 565 patients who received DAA treatment for CHC between November 2013 and June 2016 with regard to HCV genotype, fibrosis stadium, treatment and outcome...
January 29, 2018: Swiss Medical Weekly
Janne Fuglsang Hansen, Sofie Hallager, Anne Øvrehus, Nina Weis, Peer Brehm Christensen, Court Pedersen
Patients with chronic hepatitis C may have advanced fibrosis at first evaluation. Using the European Association for the Study of the Liver (EASL) definition (FibroScan® >9.5 kPa) for "late presenter for care" (LP), we found that 32% (169 of 527) of patients were LP. Being a LP was associated with increasing age and a history of alcohol overuse.
January 2018: Open Forum Infectious Diseases
Tatsunori Taniguchi, Tomohito Ohtani, Hidetaka Kioka, Yasumasa Tsukamoto, Toshinari Onishi, Kei Nakamoto, Themistoklis Katsimichas, Kaoruko Sengoku, Misato Chimura, Haruko Hashimoto, Osamu Yamaguchi, Yoshiki Sawa, Yasushi Sakata
OBJECTIVES: This study sought to investigate whether elevated liver stiffness (LS) values at discharge reflect residual liver congestion and are associated with worse outcomes in patients with heart failure (HF). BACKGROUND: Transient elastography is a newly developed, noninvasive method for assessing LS, which can be highly reflective of right-sided filling pressure associated with passive liver congestion in patients with HF. METHODS: LS values were determined for 171 hospitalized patients with HF before discharge using a Fibroscan device...
January 12, 2018: JACC. Cardiovascular Imaging
Qiang Li, Liang Chen, Yu Zhou
Noninvasive fibrosis tests have been used widely for evaluation of liver fibrosis in patients with chronic hepatitis B (CHB). We aimed to investigate the influence of antiviral treatment on FibroScan, APRI, and FIB-4 in CHB patients with significant liver histological changes (SLHC) defined as inflammatory grade ≥ A2 and/or fibrosis stage ≥ F2. A total of 104 CHB patients with SLHC at the baseline were included. FibroScan, APRI, and FIB-4 values were compared before and after 3-year entecavir (ETV) treatment...
January 19, 2018: Clinical and Experimental Medicine
H J Qu, L Wang, P H Jin, Q Gao, J X Zhou, Y Song, J Wang, Y M Jiang, L Gong, G Y Chen, J P Ding, J P Shi
Objective: To investigate the value of 1H-magnetic resonance spectroscopy ((1)H-MRS) in determining the content of liver triglyceride in patients with fatty liver disease (FLD), as well as its influencing factors. Methods: A total of 124 patients with nonalcoholic fatty liver disease (NAFLD), chronic hepatitis B (CHB), or hepatitis B complicated by FLD who underwent liver biopsy in the Affiliated Hospital of Hangzhou Normal University were enrolled, and the clinical data, serological markers, FibroScan results, and (1)H-MRS results were collected...
November 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
Mohamed Gamil, Mohamed Alboraie, Mohammad El-Sayed, Aisha Elsharkawy, Noha Asem, Tamer Elbaz, Mohammad Mohey, Bahaa Abbas, Mai Mehrez, Gamal Esmat
BACKGROUND: Serum levels of alpha-fetoprotein (AFP) were reported to increase in patients with significant or advanced hepatic fibrosis. Combination of non-invasive tests decreases the use of liver biopsy in large proportion of chronic HCV patients. AIM: To compare and combine AFP with commonly used non-invasive fibrosis tests in novel scores for prediction of different stages of hepatic fibrosis. PATIENTS AND METHODS: Six hundred and fifty two treatment naïve chronic hepatitis C patients were enrolled...
January 6, 2018: Journal of Medical Virology
Dexin Wang, Ping Zhang, Min Zhang
The aim of the present study was to evaluate the predictors for advanced liver fibrosis in patients with chronic hepatitis B virus (HBV) infection with persistently normal alanine aminotransferase (PNALT), or persistently or intermittently mildly elevated ALT (PIEALT). A total of 305 patients were included in the present study. Liver biopsies were evaluated using the METAVIR scoring system. Liver stiffness (LS) was measured using Fibroscan. Multivariate logistic regression and the area under the receiver operating characteristic curve (AUROC) were used to examine the diagnostic value of the predictors for advanced liver fibrosis...
December 2017: Experimental and Therapeutic Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"